Ophthalmic drugs contract manufacturing involves the production of eye drugs at various stages of drug development processes including development, formulation, manufacturing and packaging on a contractual basis. Growing prevalence of eye diseases such as glaucoma, cataract and diabetic retinopathy has increased the demand for various eye treatment drugs and devices.
Companies in the Ophthalmic Drugs Contract Manufacturing Market offer wide range of services including clinical trial manufacturing, registration batches manufacturing, commercial product manufacturing and packaging to meet the customized needs of clients. They employ modern manufacturing facilities and equipment to ensure drug stability, efficiency and compliance with stringent safety and quality regulations.
The ophthalmic drugs contract manufacturing market is estimated to be valued at USD 1.6 billion in 2024 and is expected to reach USD 3.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.
Key players: Key players operating in the ophthalmic drugs contract manufacturing market are Catalent Inc., AbbVie Contract Manufacturing, Ajinomoto Althea Inc., Albany Molecular Research Inc., and Recipharm AB.
Increasing R&D investments by pharmaceutical companies for developing novel treatments and surge in outsourcing of Ophthalmic Drugs Contract Manufacturing Market activities are expected to create significant growth opportunities for players.
Global expansion: Leading contract manufacturers are expanding their manufacturing facilities globally to cater to the growing demand from international drug developers and establish presence in lucrative markets like Asia Pacific and Europe.
Market drivers: Increasing prevalence of vision impairment diseases due to growing geriatric population and rising healthcare spending is a key growth driver. In addition, time and cost benefits associated with outsourcing non-core activities are prompting drug makers to engage external manufacturers.
Market restraints: Maintaining stringent compliance with quality and safety regulations during manufacturing process increases operating challenges and costs which can hamper market growth. Further, dependency on few vendors for core drug development tasks poses risk of supply disruptions.
Segment Analysis The ophthalmic drugs contract manufacturing market can be segmented based on phase into clinical and commercial. The commercial segment dominates the market as most drugs are approved and launched in the market. It holds over 70% share as majority drugs are already commercialized and manufactured through contracts. The market can also be segmented based on type of product into prescription and OTC drugs. Prescription drugs segment holds the major share owing to increasing prevalence of eye disorders like glaucoma, retinal disorders, infections etc. It accounts for around 60% share due to requirement of prescription for majority ophthalmic drugs.
Global Analysis North America region dominates the ophthalmic drugs contract manufacturing market with over 40% share. This is due to presence of major pharmaceutical companies in US and high healthcare spending on eye disorders. Europe is the second largest market followed by Asia Pacific. Asia Pacific region is expected to witness fastest growth during the forecast period. This is attributed to growing geriatric population, increasing healthcare expenditure, rising eye disorder prevalence in countries like China, India. Countries like India offer manufacturing opportunities due to availability of low cost and high skilled workforce.
Get this Report in Japanese Language: 眼科用医薬品の受託製造市場
Get this Report in Korean Language: 안과 약물 계약 제조 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
